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Osteosarcoma does not respond well to conventional dose methotrexate but does respond to high-dose methotrexate. Previous
work has indicated that this resistance may be due to impaired transport of methotrexate across the cell membrane. In this
study, the PT430 competitive displacement assay was adapted to evaluate methotrexate transport in 69 high-grade osteosarcoma
tumor samples. All samples studied were shown to have relatively impaired methotrexate transport by PT430 assay. Ninety-nine
percent of the samples had less than 20% PT430 displacement by methotrexate. Eighty-eight percent exhibited displacement by
methotrexate atless than50%of thedisplacement by trimetrexate. The highfrequency ofimpaired transport suggests thepresence
of decreased functionality of the reduced folate carrier protein. The overwhelming presence of impaired transport may explain
why methotrexate needs to be given in high doses to be eﬀective in osteosarcoma therapy and suggests that reduced folate carrier-
independent antifolates should be explored.
1.Introduction
Although osteosarcoma is uncommon among the general
population, it is the most common primary malignant
bone tumor in children and adolescents [1]. It is believed
that osteosarcoma is not responsive to conventional dose
methotrexate in contrast to high-dose methotrexate [2, 3].
Most current multi-agent treatment regimens include the
administration of high-dose methotrexate with the combi-
nation regimens having a ﬁve-year disease-free survival rate
of 60% or greater [1]. This requirement for methotrexate in
high doses for eﬀectiveness may be explained by an intrinsic
resistance of osteosarcoma to transport the drug across the
cell membrane.
Methotrexate is a structural analog of folic acid and acts
by binding and inhibiting dihydrofolate reductase (DHFR),
a key enzyme required for intracellular folate metabolism
[4]. Intracellular methotrexate undergoes polyglutamylation
whereby the polyglutamylated methotrexate is preferentially
retained in thecell and ultimatelyresultsin DHFRinhibition
[5–7]. Resistance to methotrexate in model systems has been
attributed to several causes including loss of or decreased
reduced folate carrier (RFC) function [8], increased DHFR
expression potentially as a result of gene ampliﬁcation [9],
and diminished intracellular retention of methotrexate sec-
ondary to decreased polyglutamylation [7]. Additionally,
changes in downstream eﬄux pathways could aﬀect the
intracellular concentration of methotrexate [10].2 Sarcoma
Methotrexate can be transported by at least three routes:
the folate receptors, the reduced folate carrier, and the
proton coupled folate transporter [10]. The proton coupled
folate transporter has optimal transport when in an acidic
environment [10]. The folate receptors have a higher aﬃnity
for folic acid as compared with the reduced folates while
the RFC has a higher aﬃn i t yf o rr e d u c e df o l a t e sa n d
methotrexate as compared with folic acid [3]. The RFC has
an exponentially greater cycling rate than folate receptors.
The role of folate receptors in antifolate transport may be
relevant only when RFC function is quite low unless the
antifolate in question has a particularly high aﬃnity for the
folate receptor or if the folate receptor is highly expressed
[10].
Trimetrexate does not require the RFC for cell entry;
however, limited clinical studies have been performed using
trimetrexate for the treatment of pediatric solid tumors.
Some studies have suggested that methotrexate transport
defective cells are more sensitive to trimetrexate [11]a n d
could potentially overcome methotrexate transport resis-
tance [7].
Previous work has demonstrated that over 50% of
osteosarcoma samples have at least one sequence alteration
in the RFC [12]. Another study has shown decreased
RFC mRNA expression occurs in 65% of osteosarcoma
samples obtained at biopsy and in 50% of metastatic or
recurrent samples [13]. The same study concluded that
10% of osteosarcoma samples have increased DHFR mRNA
expression at time of biopsy and 62% of metastatic or
recurrent samples have increased DHFR. PT430, a ﬂuo-
rescent lysine analog of methotrexate, competes with both
methotrexate and trimetrexate for DHFR binding. Where
PT430 is displaced by trimetrexate and not by methotrexate,
the diﬀerence in displacement can be attributed to defective
transport of methotrexate into the cell [14]. In this report
the PT430 competitive displacement assay has been adapted
to assess methotrexate transport in osteosarcoma.
2.Materialsand Methods
2.1. Sample Collection. Osteosarcoma samples were col-
lected at Memorial Sloan-Kettering Cancer Center between
November 1997 and June 2001 after obtaining written
informed consent in accordance with a biology study
approved by the Memorial Hospital Institutional Review
Board. Additional samples were collected as part of the
Children’s Oncology Group P9851 Osteosarcoma Biology
Study also after obtaining written informed consent. All
samples were conﬁrmed to have a pathologic diagnosis of
osteosarcoma.
2.2. Establishment of Short-Term Cell Cultures. Approxi-
mately 25mg of fresh tumor were ﬁnely minced using a
sterile scalpel. The minced tissue was incubated for at least
two hours in 5mLs of disaggregation media composed of
MEM-alpha media, 20%FCS (HyClone, Logan, UT), 0.6%
collagenase Type 2 (Worthington Biochemical, Lakewood,
NJ), and 0.002% DNAseI (Promega, Madison, WI). After
incubation, the slurry was passed through a 70μmc e l l
strainer. The ﬁltered solution was centrifuged at 200×g
and the resulting cell pellet was resuspended in 20mls of
cell culturemedia (MEM-alpha media+20%FCS+1% pen-
strep) and subsequently plated in a Corning T75 ﬂask. Cells
were passaged after reaching 80% conﬂuence.
2.3. PT430 Competitive Displacement Assay. The PT430
competitive displacement assay was performed as previously
described [8, 14] with the following modiﬁcations. The
assay was performed with the osteosarcoma cells placed in
suspension as described originally with the cells trypsinized
to place them in suspension. The trypsinized cells were
c e n t r i f u g e da t2 0 0 x ga n dt h er e s u l t i n gc e l lp e l l e tw a s
resuspendedin5mLs ofmedia.Cellswerekeptinsuspension
through the completion of the assay. Cells were incubated in
20μM PT430 for four hours at 37◦ instead of the referenced
two hours. Methotrexate and trimetrexate were added to
ﬁnal concentrations of 1μM each. PT430 was synthesized
a n dk i n d l yp r o v i d e db yD r .J o e lW r i g h ta n dD r .A n d r e
RosowskyoftheDana-Farber CancerInstitute.Methotrexate
and trimetrexate displacement were calculated relative to the
peak uptake correcting all samples for autoﬂuorescence as
has been described previously.
2.4. GD2 Antibody Labeling. GD2 antibody labeling was
performed to verify that the cell population consisted of
osteosarcoma cells and not ﬁbroblasts. 1×107/ml cells were
incubated with 100μg 3F8 mouse monoclonal antibody for
1 hour at 4 degrees C on a rotating platform. The 3F8
antibody is speciﬁc for the GD2 cell surface protein which
is present on osteosarcoma cells but is absent on ﬁbroblasts.
Following incubation with the primary antibody, cells were
washed twice with PBS and then incubated with 50μgo f
mouse IgG-FITC secondary antibody (Research Diagnostics
Inc., Flanders, NJ). Secondary antibody incubation was
for 15 minutes at 4 degrees C on a rotating platform.
After incubation, cells were washed twice with PBS. The
remaining pellet was resuspended in PBS and analyzed by
ﬂow cytometry. (The 3F8 antibody was kindly provided
b yD r .N .K .C h e u n g ,M e m o r i a lS l o a n - K e t t e r i n gC a n c e r
Center).
3.Results
Tumor samples were obtained from 69 patients with con-
ﬁrmed diagnosis of osteosarcoma. Fifty of the 69 samples
were obtained at time of biopsy, 11 samples were obtained
at time of deﬁnitive surgery, and the remaining eight were
obtained at the time of relapse or at the site of metastatic
disease. GD2 antibody labeling of a subset of patient samples
demonstratedthatmorethaneighty-ﬁvepercentofcellswere
osteosarcoma tumor cells (data not shown).
PT430 displacement by methotrexate and trimetrexate
in the 69 osteosarcoma patient samples is summarized in
Table 1 and Figure 1. Sixty eight of 69 samples (99%)
had less than 20% displacement by methotrexate with 17
samples evidencing a complete lack of PT430 displacementSarcoma 3
Table 1: Displacement of methotrexate and trimexate by PT430 grouped by sample type.
All samples Biopsy Deﬁnitive surgery Metastatic disease
or relapse
% PT430 Displacement by
methotrexate
n 69 50 11 8
Range 0%–50.97% 0%–19.28% 0%–50.97% 1.13%–14.71%
Median 3.10% 2.29% 5.81% 7.62%
Average 4.88% 3.60% 8.89% 7.36%
% PT430 Displacement by
trimetrexate
Range 3.27%–86.69% 3.27%–59.01% 6.84%–86.69% 12.48%–83.13%
Median 21.05% 18.24% 30.50% 27.23%
Average 24.66% 20.63% 32.81% 38.69%
MTX:TMTX Diﬀerential
displacement ratioa
Range 0.00–3.60 0.00–3.60 0.00–0.95 0.04–0.64
Median 0.15 0.12 0.22 0.13
Average 0.25 0.24 0.27 0.25
aThe MTX:TMTX diﬀerential displacement ratio represents the percentage of PT430 displaced by methotrexate in relation to the percentage of PT430
displacedby trimetrexate. For example,a samplewith methotrexate displacementof 25% and trimetrexate displacementof 50% would have an MTX:TMTX
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Figure 1: Summary of percentage PT430 displacement by
methotrexate and trimetrexate in 69 osteosarcoma patient samples.
Methotrexate displacement of PT430 was less than 20% in 99% of
the samples.
by methotrexate. In comparison, trimetrexate displacement
of PT430 was measurable in all 69 patient samples. Displace-
ment by methotrexate among the 69 samples ranged from
0% to 51% (mean=4.9%); displacement by trimetrexate
ranged from 3.3% to 86.7% (mean=24.7%).
In 60 of the 69 samples, displacement by methotrexate
(MTX) was less than half the displacement by trimetrexate
(TMTX) suggesting an RFC-mediated transport defect. This
is represented by an MTX:TMTX diﬀerential displacement
ratio where the percentage displacement by methotrexate is
compared to the percentage displacement by trimetrexate
(Table 1). In two of the 69 samples, PT430 displacement by
methotrexate was greater than displacement by trimetrexate
which may be related to P-glycoprotein expression. Nine
samples had elevated peak PT430 accumulation signifying
possible DHFR overexpression [8, 15].
All 50 biopsy samples exhibited less than 20% me-
thotrexate displacement of PT430 (range=0% to 19.3%;
mean=3.6%) with 16 samples displaying 0% displace-
ment by methotrexate. Trimetrexate displacement of PT430
ranged from 3.3% to 59% (mean=20.6%). Forty ﬁve of the
50 biopsy samples (90%) exhibited methotrexate displace-
ment of PT430 at less than half of the trimetrexate displace-
ment. The average MTX:TMTX diﬀerential displacement
ratio of the biopsy samples was 0.24 indicating that, on
average, methotrexate displacement of PT430 was only 24%
of the PT430 amount that was displaced by trimetrexate.
Of the 11 deﬁnitive surgery samples, 10 samples dis-
played less than 20% methotrexate displacement of PT430
(range=0% to 51%; mean=8.9%). One sample displayed
0% methotrexate displacement of PT430 and one sample
displayed 51% methotrexate displacement. Trimetrexate
displacement of PT430 ranged from 6.8% to 86.7% with an
average of 32.8%. Nine of the 11 deﬁnitive surgery samples
(82%) displayed methotrexate displacement of PT430 at less
than half of the corresponding trimetrexate displacement
with an average MTX:TMTX diﬀerential displacement ratio
of 0.27.
All eight samples representative of metastatic disease
or relapse had methotrexate displacement of less than
20% (range=1.1% to 14.7%; mean=7.4%). Six of the
eight samples (75%) showed methotrexate displacement at
less than half of trimetrexate displacement. Trimetrexate
displacement for the eight samples ranged from 12.5% to
93.1%; mean=38.7%. The average MTX:TMTX diﬀerential
displacement ratio was 0.25.
4.Discussion
Methotrexate treatment is a valuable component of current
treatment protocols for osteosarcoma [16–19]. Unfortu-
nately, high-dose methotrexate therapy is associated with
considerable costs and morbidity, although signiﬁcant
neurotoxicity and renal toxicity are rarely observed. The
improved eﬃcacy of high-dose methotrexate as compared to
conventional dose methotrexate suggests that osteosarcoma
may have intrinsic methotrexate resistance which can be4 Sarcoma
overcome by achieving a high extracellular drug concentra-
tion [4, 10]. One possibility for intrinsic methotrexate resis-
tance would be a transport defect. A clearer understanding
of the relative methotrexate-resistance of osteosarcoma may
direct better treatment strategies.
This studysoughttodeterminewhethertheimpaired cell
entry of methotrexate is involved in the observed intrinsic
resistance to methotrexate in osteosarcoma. When PT430
is displaced by trimetrexate and not by methotrexate, the
diﬀerence in displacement can be attributed to defective
transport of methotrexate into the cell [14]. Currently, there
is no standard for what is considered functionally defective
methotrexate transport in osteosarcoma. For the PT430
assays described in this study, methotrexate was added to a
ﬁnal concentration of 1μM. Of note, this is a clinically rel-
evant methotrexate level, and typical plasma concentrations
following high-dose methotrexate for osteosarcoma patients
are <10μMa t2 4h o u r sa n d<1μMa t4 8h o u r s .I na c u t e
lymphocytic leukemia, defective transport has been deﬁned
as less than 40% displacement of PT430 by methotrexate
[20]. A recent study investigating impairments in antifolate
transport in retinoblastoma tumors suggested a reduced
folate carrier protein defect was indicated in those samples
whose PT430 displacement by methotrexate was less than
half the displacement by trimetrexate [12].
In this study, 99% of the osteosarcoma patient sam-
ples exhibited less than 20% displacement of PT430 by
methotrexate, and 88% had methotrexate displacement at
lessthanhalfofthecorrespondingtrimetrexate displacement
of PT430 (n=69). This is strong evidence that osteosarcoma
harborssomelevelofintrinsic resistancetomethotrexatedue
to impaired transport. Only nine of the 69 samples (13%)
exhibited elevated peak PT430 levels suggestive of DHFR
overexpression. These results suggest that methotrexate
resistance is a result of impaired transport via the reduced
folate carrier rather than DHFR overexpression. Given the
evident intrinsic methotrexate resistance in osteosarcoma,
evaluation of antifolate agents that do not rely on transport
via the RFC is warranted for recurrent or refractory disease.
Potentially, the degree of intrinsic methotrexate resistance
could be determined at diagnosis and could help deﬁne
individualized therapy for osteosarcoma.
Forty ﬁve of the 50 biopsy samples (90%) had an
MTX:TMTX diﬀerential displacement ratio of <0.50; that
is, displacement of PT430 by methotrexate was less than
half of the displacement by trimetrexate. The human
lymphoblast cell line CCRF-CEM is known to be sensitive
to methotrexate and exhibited an MTX:TMTX diﬀerential
displacement ratio of 0.99 (data not shown). Nine of 11
patient samples (82%) taken at time of deﬁnitive surgery
exhibited methotrexate displacement at less than half of
the corresponding trimetrexate displacement. Similarly, six
of eight samples (75%) taken either at time of relapse or
from metastatic disease had methotrexate displacement at
less than half of trimetrexate displacement. In summary,
functional methotrexate defects were observed in osteosar-
coma regardless of sample type: biopsy, deﬁnitive resection,
or relapse.
Since methotrexate enters the cell primarily through
the reduced folate carrier, it could be plausibly concluded
that the prevalence of impaired methotrexate transport in
osteosarcoma is due to altered function of the reduced
folate carrier. It has been previously reported that over
50% of osteosarcoma samples have decreased reduced folate
carrier expression at time of diagnosis as determined by
semiquantitative PCR [13]. The decreased reduced folate
carrier expression was associated with inferior response
to preoperative chemotherapy, but functional methotrexate
transport was not assessed in these samples.
Sequence alterations of the reduced folate carrier have
been shown to occur in osteosarcoma. The functional sig-
niﬁcance of several reduced folate carrier sequence variants
was evaluated by transfecting several diﬀerentaltered human
reduce folate carrier fusion proteins into a reduced folate
carrier-null hamster cell line [21] or null HeLa cell line
[22]. Four of the altered hamster lines resulted in less
eﬀectivetransport ofmethotrexate as comparedto wild type.
Likewise, four of the altered HeLa lines resulted in either
reduced or abolished methotrexate transport in comparison
to wild type. It is expected that these sequence variants
in human osteosarcoma cell lines would yield a similar
result. Other reported alterations to the reduced folate
carrier include multiple sequence variants in exons 2 and 3
[9], promoter methylation [23], and high-frequency splice
variants [24].
Although therapeutically informative, functional trans-
port assays are not likely to be prognostic given the high
frequency of transport defects. Changes in reduced folate
carrier expression level as opposed to sequence alterations
m a yb ep r o g n o s t i ca st h er e l e v a n c em a yb et h em e c h a n i s m
of functional inactivation. It remains unclear why even at
diagnosis, priortomethotrexate exposure, themethotrexate-
reduced folate carrier transport pathway is functionally
inactivated. Further characterization of the reduced folate
carrier alterations may provide more insight into basic folate
transport mechanisms and steps in osteosarcoma tumor
pathogenesis.
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